Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.65 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.63 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.63 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | IKZF2 | Q9UKS7 | 9/20 | 0.61 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29480083 | 1.00 | CRBN (0.65) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL17423633 | 0.91 | CRBN (0.65) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL25740848 | 0.91 | CRBN (0.67) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| Hydrochloric Acid SCHEMBL17420696 | 0.90 | CRBN (0.64) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL25516162 | 0.89 | CRBN (0.52) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL15128599 | 0.89 | CRBN (0.68) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL24741264 | 0.88 | IKZF2 (0.61) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL23657092 | 0.88 | CRBN (0.61) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL25469611 | 0.87 | CRBN (0.69) | CRBNDDB1GSPT1IKZF3CYP2C19 | |
| SCHEMBL15128601 | 0.87 | CRBN (0.69) | CRBNDDB1GSPT1IKZF3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| CN-116583509-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| EP-3399981-B1 | SOLID FORMS OF 2-(4-CHLOROPHENYL)-N-((2-2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL) METHYL)-2,2-DIFLUOROACETAMIDE, AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | CELGENE CORP (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023115149-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122581-A2 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115150-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023078410-A1 | COMPOUND HAVING ACTIVITY OF DEGRADING GSPT1 AND APPLICATION THEREOF | 上海美志医药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| CN-114262319-B | Bifunctional molecule, preparation method and application thereof | 南昌奥瑞药业有限公司 | 2023-05-05 | — | — | CN | disclosed |
| WO-2022257897-A1 | ISOINDOLINONE COMPOUNDS, AND USES THEREOF | HANGZHOU GLUBIO PHARMACEUTICAL CO., LTD. (CN) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022254376-A1 | NEODEGRADER CONJUGATES | ORUM THERAPEUTICS, INC. (KR) | 2022-12-08 | — | — | WO | disclosed |
| CN-114262319-A | Bifunctional molecules, preparation method and application thereof | 南昌奥瑞药业有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2020242960-A1 | COMPOUNDS TARGETING PROTEINS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| EP-3166937-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2019-09-04 | — | — | EP | disclosed |
| WO-2019136016-A1 | ISOTOPOLOGUES OF 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE | CELGENE CORPORATION (US) | 2019-07-11 | — | — | WO | disclosed |
| EP-2985281-B1 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CELGENE CORP (US) | 2017-12-27 | — | — | EP | disclosed |
| WO-2017214014-A1 | TREATMENT OF A HEMATOLOGIC MALIGNANCY WITH 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE | CELGENE CORPORATION (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2016007848-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION (US) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | CRBN 1484/4885DDB1 530/4885GSPT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.